Inicio
Resultado de la búsqueda
8 búsqueda de la palabra clave 'liver transplantation'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigaciónLiver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region / Sergio Iván Hoyos Duque
Título : Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2021 Títulos uniformes : Transplant International Idioma : Inglés (eng) Palabras clave : allocation hepatocellular carcinoma liver transplantation selection Resumen : This study aimed to compare liver transplantation (LT) outcomes and evaluate the potential rise in numbers of LT candidates with hepatocellular carcinoma (HCC) of different allocation policies in a high waitlist mortality region. Three policies were applied in two Latin American cohorts (1085 HCC transplanted patients and 917 listed patients for HCC): (i) Milan criteria with expansion according to UCSF downstaging (UCSF-DS), (ii) the AFP score, and (iii) restrictive policy or Double Eligibility Criteria (DEC; within Milan + AFP score ≤2). Increase in HCC patient numbers was evaluated in an Argentinian prospective validation set (INCUCAI; NCT03775863). Expansion criteria in policy A showed that UCSF-DS [28.4% (CI 12.8–56.2)] or “all-comers” [32.9% (CI 11.9–71.3)] had higher 5-year recurrence rates compared to Milan, with 10.9% increase in HCC patients for LT. The policy B showed lower recurrence rates for AFP scores ≤2 points, even expanding beyond Milan criteria, with a 3.3% increase. Patients within DEC had lower 5-year recurrence rates compared with those beyond DEC [13.3% (CI 10.1–17.3) vs 24.2% (CI 17.4–33.1; P = 0.0006], without significant HCC expansion. In conclusion, although the application of a stricter policy may optimize the selection process, this restrictive policy may lead to ethical concerns in organ allocation (NCT03775863). Mención de responsabilidad : Federico Pinero, Margarita Anders, Ilka F. Boin, Aline Chagas, Emilio Quinonez, Sebastian Marciano, Mario Vilatoba, Luisa Santos, Sergio Hoyos Duque, Agnaldo Soares Lima, Josemaria Menendez, Martin Padilla, Jaime Poniachik, Rodrigo Zapata, Alejandro Soza, Martin Maraschio, Ricardo Chong Menendez, Linda Munoz, Diego Arufe, Rodrigo Figueroa, Elaine Cristina de Ataide, Claudia Maccali, Rodrigo Vergara Sandoval, Carla Bermudez, Luis G. Podesta, Lucas McCormack, Adriana Varon, Adrian Gadano, Juan Mattera, Federico Villamil, Fernando Rubinstein, Flair Carrilho & Marcelo Silva Referencia : Transpl Int. 2021 Jan;34(1):97-109. DOI (Digital Object Identifier) : 10.1111/tri.13767 PMID : 33040420 En línea : https://onlinelibrary.wiley.com/doi/10.1111/tri.13767 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5880 Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region [documento electrónico] / Sergio Iván Hoyos Duque, . - 2021.
Obra : Transplant International
Idioma : Inglés (eng)
Palabras clave : allocation hepatocellular carcinoma liver transplantation selection Resumen : This study aimed to compare liver transplantation (LT) outcomes and evaluate the potential rise in numbers of LT candidates with hepatocellular carcinoma (HCC) of different allocation policies in a high waitlist mortality region. Three policies were applied in two Latin American cohorts (1085 HCC transplanted patients and 917 listed patients for HCC): (i) Milan criteria with expansion according to UCSF downstaging (UCSF-DS), (ii) the AFP score, and (iii) restrictive policy or Double Eligibility Criteria (DEC; within Milan + AFP score ≤2). Increase in HCC patient numbers was evaluated in an Argentinian prospective validation set (INCUCAI; NCT03775863). Expansion criteria in policy A showed that UCSF-DS [28.4% (CI 12.8–56.2)] or “all-comers” [32.9% (CI 11.9–71.3)] had higher 5-year recurrence rates compared to Milan, with 10.9% increase in HCC patients for LT. The policy B showed lower recurrence rates for AFP scores ≤2 points, even expanding beyond Milan criteria, with a 3.3% increase. Patients within DEC had lower 5-year recurrence rates compared with those beyond DEC [13.3% (CI 10.1–17.3) vs 24.2% (CI 17.4–33.1; P = 0.0006], without significant HCC expansion. In conclusion, although the application of a stricter policy may optimize the selection process, this restrictive policy may lead to ethical concerns in organ allocation (NCT03775863). Mención de responsabilidad : Federico Pinero, Margarita Anders, Ilka F. Boin, Aline Chagas, Emilio Quinonez, Sebastian Marciano, Mario Vilatoba, Luisa Santos, Sergio Hoyos Duque, Agnaldo Soares Lima, Josemaria Menendez, Martin Padilla, Jaime Poniachik, Rodrigo Zapata, Alejandro Soza, Martin Maraschio, Ricardo Chong Menendez, Linda Munoz, Diego Arufe, Rodrigo Figueroa, Elaine Cristina de Ataide, Claudia Maccali, Rodrigo Vergara Sandoval, Carla Bermudez, Luis G. Podesta, Lucas McCormack, Adriana Varon, Adrian Gadano, Juan Mattera, Federico Villamil, Fernando Rubinstein, Flair Carrilho & Marcelo Silva Referencia : Transpl Int. 2021 Jan;34(1):97-109. DOI (Digital Object Identifier) : 10.1111/tri.13767 PMID : 33040420 En línea : https://onlinelibrary.wiley.com/doi/10.1111/tri.13767 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5880 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001818 AC-2021-130 Archivo digital Producción Científica Artículos científicos Disponible
Título : Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2021 Títulos uniformes : Liver International Idioma : Inglés (eng) Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5193 Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort [documento electrónico] / Sergio Iván Hoyos Duque, . - 2021.
Obra : Liver International
Idioma : Inglés (eng)
Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5193 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001640 AC-2020-134 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, Fecha de publicación : 2020 Títulos uniformes : World Journal of Transplantation Idioma : Inglés (eng) Palabras clave : Liver transplantation Recurrence Systemic therapies Hepatocellular carcinoma Resumen : Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades, effective systemic treatments for HCC, including tyrosine kinase inhibitors and immunotherapy, have been approved. We describe the clinical scenario of a patient with recurrence of HCC five years after LT, who received lenvatinib as first-line systemic therapy to introduce systemic treatment options in this clinical setting. In this opinion review, we detail first and second-line systemic treatment options, focusing on those feasible for patients with recurrent HCC after LT. Several trials have evaluated new drugs to treat HCC patients in first and second-line therapy, but patients with recurrent HCC after LT have been excluded from these trials. Consequently, most of the evidence comes from observational retrospective studies. Whether tyrosine kinase inhibitors will remain the primary therapeutic approach in these patients, due to a relative contraindication for immunotherapy, may be clarified in the near future. Mención de responsabilidad : Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva Referencia : World J Transplant. 2020 Nov 28;10(11):297-306. DOI (Digital Object Identifier) : 10.5500/wjt.v10.i11.297 PMID : 33312891 Derechos de uso : CC BY-NC En línea : https://www.wjgnet.com/2220-3230/full/v10/i11/297.htm Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5163 Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? [documento electrónico] / Juan Ignacio Marín Zuluaga, . - 2020.
Obra : World Journal of Transplantation
Idioma : Inglés (eng)
Palabras clave : Liver transplantation Recurrence Systemic therapies Hepatocellular carcinoma Resumen : Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades, effective systemic treatments for HCC, including tyrosine kinase inhibitors and immunotherapy, have been approved. We describe the clinical scenario of a patient with recurrence of HCC five years after LT, who received lenvatinib as first-line systemic therapy to introduce systemic treatment options in this clinical setting. In this opinion review, we detail first and second-line systemic treatment options, focusing on those feasible for patients with recurrent HCC after LT. Several trials have evaluated new drugs to treat HCC patients in first and second-line therapy, but patients with recurrent HCC after LT have been excluded from these trials. Consequently, most of the evidence comes from observational retrospective studies. Whether tyrosine kinase inhibitors will remain the primary therapeutic approach in these patients, due to a relative contraindication for immunotherapy, may be clarified in the near future. Mención de responsabilidad : Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva Referencia : World J Transplant. 2020 Nov 28;10(11):297-306. DOI (Digital Object Identifier) : 10.5500/wjt.v10.i11.297 PMID : 33312891 Derechos de uso : CC BY-NC En línea : https://www.wjgnet.com/2220-3230/full/v10/i11/297.htm Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5163 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001596 AC-2020-102 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-102.pdfAdobe Acrobat PDF
Título : Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents Otros títulos : Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, ; Óscar Mauricio Santos Sánchez, Fecha de publicación : 2019 Títulos uniformes : Medicina (Buenos Aires) Idioma : Inglés (eng) Palabras clave : Antiviral agents drug therapy hepatitis C chronic hepatitis liver transplantation treatment outcome Resumen : There are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p Mención de responsabilidad : Adriana Varón, Luisa Santos, Mónica Tapias, Clara Cáez, Juan Ignacio Marín, Oscar Santos, Martín Garzón, Oscar Beltrán, Andrés Gómez-Aldana, Ismael J Yepes, Martín Rondón, Diego Rosselli Referencia : Medicina (B Aires). 2019;79(1):29-36 PMID : 30694186 Derechos de uso : CC BY-NC En línea : http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-768020190001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4264 Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents = Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Óscar Mauricio Santos Sánchez, . - 2019.
Obra : Medicina (Buenos Aires)
Idioma : Inglés (eng)
Palabras clave : Antiviral agents drug therapy hepatitis C chronic hepatitis liver transplantation treatment outcome Resumen : There are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p Mención de responsabilidad : Adriana Varón, Luisa Santos, Mónica Tapias, Clara Cáez, Juan Ignacio Marín, Oscar Santos, Martín Garzón, Oscar Beltrán, Andrés Gómez-Aldana, Ismael J Yepes, Martín Rondón, Diego Rosselli Referencia : Medicina (B Aires). 2019;79(1):29-36 PMID : 30694186 Derechos de uso : CC BY-NC En línea : http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-768020190001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4264 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001243 AC-2019-032 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2019-032.pdfAdobe Acrobat PDF
Título : An experience of liver transplantation in Latin America : a medical center in Colombia Otros títulos : Experiencia de trasplante hepático en Latinoamérica: en un centro médico en Colombia Tipo de documento : documento electrónico Autores : Óscar Mauricio Santos Sánchez, ; Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Álvaro Mena Hurtado, ; Carlos Ernesto Guzmán Luna, ; Sergio Iván Hoyos Duque, ; Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2015 Títulos uniformes : Colombia Médica Idioma : Inglés (eng) Palabras clave : Liver transplantation cirrhosis liver graft rejection immunosuppressive Resumen : Objectives: Liver transplantation is the treatment of choice for acute and chronic liver failure, for selected cases of tumors, and for conditions resulting from errors in metabolism. This paper reports the experience of a medical center in Latin America. Methods:Were conducted 305 orthotopic liver transplantations on 284 patients between 2004 and 2010. Of these patients, 241 were adults undergoing their first transplantation. Results: The average age of patients was 52 years old, and 62% of the individuals were male. The most common indication was alcoholic cirrhosis. The rate of patient survival after 1 and 5 years was 82 and 72% respectively. The rate of liver graft survival after 1 and 5 years was 78 and 68% respectively. The main cause of death was sepsis. Complications in the hepatic artery were documented for 5% of the patients. Additionally, 14.5% of the patients had complications in the biliary tract. Infections were found in 41% of the individuals. Acute rejection was observed in 30% of the subjects, and chronic rejection in 3%. Conclusion:In conclusion, liver transplantation at our medical center in Colombia offers good mid-term results, with a complication rate similar to that reported by other centers around the world. Mención de responsabilidad : Oscar Santos, Mauricio Londoño, Juan Marín, Octavio Muñoz, Álvaro Mena, Carlos Guzmán, Sergio Hoyos, Juan Restrepo, María Arbeláez, Gonzalo Correa Referencia : Colomb Med (Cali). 2015 Mar 30;46(1):8-13. DOI (Digital Object Identifier) : 10.25100/cm.v46i1.1400 PMID : 26019379 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1400 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3879 An experience of liver transplantation in Latin America : a medical center in Colombia = Experiencia de trasplante hepático en Latinoamérica: en un centro médico en Colombia [documento electrónico] / Óscar Mauricio Santos Sánchez, ; Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Álvaro Mena Hurtado, ; Carlos Ernesto Guzmán Luna, ; Sergio Iván Hoyos Duque, ; Juan Carlos Restrepo Gutiérrez, . - 2015.
Obra : Colombia Médica
Idioma : Inglés (eng)
Palabras clave : Liver transplantation cirrhosis liver graft rejection immunosuppressive Resumen : Objectives: Liver transplantation is the treatment of choice for acute and chronic liver failure, for selected cases of tumors, and for conditions resulting from errors in metabolism. This paper reports the experience of a medical center in Latin America. Methods:Were conducted 305 orthotopic liver transplantations on 284 patients between 2004 and 2010. Of these patients, 241 were adults undergoing their first transplantation. Results: The average age of patients was 52 years old, and 62% of the individuals were male. The most common indication was alcoholic cirrhosis. The rate of patient survival after 1 and 5 years was 82 and 72% respectively. The rate of liver graft survival after 1 and 5 years was 78 and 68% respectively. The main cause of death was sepsis. Complications in the hepatic artery were documented for 5% of the patients. Additionally, 14.5% of the patients had complications in the biliary tract. Infections were found in 41% of the individuals. Acute rejection was observed in 30% of the subjects, and chronic rejection in 3%. Conclusion:In conclusion, liver transplantation at our medical center in Colombia offers good mid-term results, with a complication rate similar to that reported by other centers around the world. Mención de responsabilidad : Oscar Santos, Mauricio Londoño, Juan Marín, Octavio Muñoz, Álvaro Mena, Carlos Guzmán, Sergio Hoyos, Juan Restrepo, María Arbeláez, Gonzalo Correa Referencia : Colomb Med (Cali). 2015 Mar 30;46(1):8-13. DOI (Digital Object Identifier) : 10.25100/cm.v46i1.1400 PMID : 26019379 Derechos de uso : CC BY En línea : https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1400 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3879 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000459 AC-2015-012 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2015-012.pdfAdobe Acrobat PDF
